The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies. The main questions it aims to answer are: * Does GLP-1 and GIP agonist increase the rate of inadequate bowel preparation? * Does the quality of bowel preparation differ in patients who hold vs. those who continue a single dose of their GLP-1 or GIP agonist medication? * Are there any differences in the rates of complications gastric aspiration in patients who hold vs. continue a single dose of their GLP-1 or GIP agonist medication?
Eligibility Criteria
Inclusion Criteria: * Adult patient (Age 18 years or older) * Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy * Using a GLP-1 or GIP agonist at a stable dose for at least one month Exclusion Criteria: * Unable to provide informed consent, e.g., dementia * Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy) * Risk factors for inadequate bowel preparation besides diabetes and obesity with a likelihood ratio of 1.6 or greater: 1. Cirrhosis 2. Parkinson's disease 3. Dementia 4. Tricyclic antidepressant use 5. Opioid use 6. Gastroparesis\* or suspected gastric outlet obstruction on pre-procedure imaging (\*defined based on a documented 4-hour solid phase gastric emptying study or prior history of retained gastric contents during upper endo